SARS-CoV-2, Virus Like Particles (Ha-CoV2) Omicron (BA.2.75) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike K147E, Spike W152R, Spike F157L, Spike I210V, Spike V213G, Spike G257S, Spike G339H, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike G446S, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size:

• 25 X 200 µL ~100 wells/96 well plate
• 60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (BA.4.6) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike L24S, Spike del25/27, Spike del69/70, Spike G142D, Spike V213G, Spike G339D, Spike R346T, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike L452R, Spike S477N, Spike T478K, Spike E484A, Spike F486V, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N658S, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size:

• 25 X 200 µL ~100 wells/96 well plate
• 60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1.16) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike L24S, Spike 25/27del, Spike V83A, Spike G142D, Spike Del144/144, Spike H146Q, SpikeE180V, Spike Q183E, Spike V213E, Spike G252V, Spike G339H, Spike R346T, Spike L368I, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N, Spike N440K, Spike V445P, Spike G446S,Spike N460K, Spike S477N, Spike T478R, Spike E484A, Spike F486P, Spike F490S, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size:

• 25 X 200 µL ~100 wells/96 well plate
• 60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.

SARS-CoV-2, Virus Like Particles (Ha-CoV2) (XBB.1): hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for XBB.1 strain. The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Spike Mutations: Spike T19I, Spike L24S, Spike del25/27, Spike V83A, Spike G142D,Spike del144/144, Spike H146Q, Spike Q183E, Spike V213E, Spike G252V, Spike G339H, Spike R346T, Spike L368I, Spike S371F, Spike S373P, Spike S375F, Spike T376A, Spike D405N, Spike R408S, Spike K417N,Spike N440K, Spike V445P, Spike G446S, Spike N460K, Spike S477N, Spike T478K, Spike E484A, Spike F486S, Spike F490S, Spike Q498R, Spike N501Y, Spike Y505H, Spike D614G, Spike H655Y, Spike N679K, Spike P681H, Spike N764K, Spike D796Y, Spike Q954H, Spike N969K Size:

• 25 X 200 µL ~100 wells/96 well plate
• 60x Conc. 5 x 100 µL

Reporter: Available with Firefly luciferase, GFP, or RFP Formulation & Storage: Store at -80°C. Intended for research use only, not for human, therapeutic, or diagnostic applications.